Collegium Pharmaceutical (COLL) vs Gyre Therapeutics (GYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Gyre Therapeutics (GYRE) has outperformed Collegium Pharmaceutical (COLL) over the past year, losing 7.4% versus a loss of 33.3%. Over five years, COLL leads with a +4.5% price change compared with -88.7% for GYRE. Collegium Pharmaceutical is the larger company by market cap ($719.8 million vs $716.8 million), about 1.0 times the size.
On valuation, Collegium Pharmaceutical trades at a lower forward P/E (3.3x vs 112.7x for Gyre Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | GYRE |
|---|---|---|
| Share price | $22.11 | $6.76 |
| Market cap | $719.80M | $716.79M |
| 1-day change | +0.82% | -3.98% |
| YTD return | -52.25% | -4.25% |
| 1-year return | -33.26% | -7.40% |
| 5-year return | +4.53% | -88.73% |
| P/E ratio (TTM) | 17.41 | — |
| Forward P/E | 3.33 | 112.67 |
| EPS (TTM) | $1.27 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.79 | $9.42 |
| 52-week low | $21.43 | $5.44 |
| Distance from 52-week high | -56.47% | -28.24% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +121.62% | +176.18% |
| Average volume | 749.33K | 105.93K |
| Shares outstanding | 32.56M | 106.03M |
| Employees | 423 | 625 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GYRE has outperformed COLL by 25.9 percentage points over the past year.
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
COLL vs GYRE FAQ
Which is bigger, Collegium Pharmaceutical or Gyre Therapeutics?
Collegium Pharmaceutical (COLL) is larger, with a market capitalization of $719.80M compared with $716.79M for Gyre Therapeutics (GYRE).
Which stock has performed better over the past year, COLL or GYRE?
GYRE returned -7.40% over the past 12 months, compared with -33.26% for COLL (price return, excluding dividends). Past performance does not predict future results.
Are Collegium Pharmaceutical and Gyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.